Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening

Journal of Medicinal Chemistry

Volumn 59, Issue 11, 2016, Pages 5542-5554

  Lund, Bjarte Aarmo ^a   Christopeit, Tony ^a   Guttormsen, Yngve ^a   Bayer, Annette ^a   Leiros, Hanna Kirsti S ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AVIBACTAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BETA LACTAMASE OXACILLINASE 48; BETA LACTAMASE OXACILLINASE 48 INHIBITOR; CEFEPIME; CENTA; IMIPENEM; MEROPENEM; NITROCEFIN; PENICILLIN G; UNCLASSIFIED DRUG;

ANTAGONIST POTENCY; ANTIBIOTIC RESISTANCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME INHIBITION ASSAY; IC50; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOLECULAR MODEL; PRECLINICAL STUDY; SYNTHESIS;

BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MICROBIAL; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE;

EID: 84974621950     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00660     Document Type: Article

References (53)

1. The Bacterial Challenge: Time to React; EMEA/576176/2009; ECDC/EMEA Joint Working Group: Stockholm, Sweden, 2009.
2. Papp-Wallace, K. M.; Endimiani, A.; Taracila, M. A.; Bonomo, R. A. Carbapenems: past, present, and future Antimicrob. Agents Chemother. 2011, 55, 4943-4960 10.1128/AAC.00296-11
3. Poirel, L.; Potron, A.; Nordmann, P. OXA-48-like carbapenemases: the phantom menace J. Antimicrob. Chemother. 2012, 67, 1597-1606 10.1093/jac/dks121
4. Mathers, A. J.; Hazen, K. C.; Carroll, J.; Yeh, A. J.; Cox, H. L.; Bonomo, R. A.; Sifri, C. D. First clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniae in the United States: the "menace" arrives in the new world J. Clin. Microbiol. 2013, 51, 680-683 10.1128/JCM.02580-12
5. Drawz, S. M.; Bonomo, R. a. Three decades of β-lactamase inhibitors Clin. Microbiol. Rev. 2010, 23, 160-201 10.1128/CMR.00037-09
6. Danel, F.; Paetzel, M.; Strynadka, N. C. J.; Page, M. G. P. Effect of Divalent Metal Cations on the Dimerization of OXA-10 and -14 Class D β-Lactamases from Pseudomonas aeruginosa Biochemistry 2001, 40, 9412-9420 10.1021/bi0025969
7. Vercheval, L.; Bauvois, C.; di Paolo, A.; Borel, F.; Ferrer, J.-L.; Sauvage, E.; Matagne, A.; Frère, J.-M.; Charlier, P.; Galleni, M.; Kerff, F. Three factors that modulate the activity of class D β-lactamases and interfere with the post-translational carboxylation of Lys70 Biochem. J. 2010, 432, 495-504 10.1042/BJ20101122
8. Golemi, D.; Maveyraud, L.; Vakulenko, S.; Samama, J. P.; Mobashery, S. Critical involvement of a carbamylated lysine in catalytic function of class D β-lactamases Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 14280-14285 10.1073/pnas.241442898
9. Toussaint, K. A.; Gallagher, J. C. β -Lactam/β-lactamase inhibitor combinations: from then to now Ann. Pharmacother. 2015, 49, 86-98 10.1177/1060028014556652
10. Ehmann, D. E.; Jahic, H.; Ross, P. L.; Gu, R.-F.; Hu, J.; Durand-Réville, T. F.; Lahiri, S.; Thresher, J.; Livchak, S.; Gao, N.; Palmer, T.; Walkup, G. K.; Fisher, S. L. Kinetics of avibactam inhibition against Class A, C, and D β-lactamases J. Biol. Chem. 2013, 288, 27960-27971 10.1074/jbc.M113.485979
11. Garber, K. A β-lactamase inhibitor revival provides new hope for old antibiotics Nat. Rev. Drug Discovery 2015, 14, 445-447 10.1038/nrd4666
12. Lahiri, S. D.; Mangani, S.; Jahić, H.; Benvenuti, M.; Durand-Reville, T. F.; De Luca, F.; Ehmann, D. E.; Rossolini, G. M.; Alm, R. A.; Docquier, J.-D. Molecular basis of selective inhibition and slow reversibility of Avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48 ACS Chem. Biol. 2015, 10, 591-600 10.1021/cb500703p
13. Drawz, S. M.; Papp-Wallace, K. M.; Bonomo, R. a. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world Antimicrob. Agents Chemother. 2014, 58, 1835-1846 10.1128/AAC.00826-13
14. Humphries, R. M.; Yang, S.; Hemarajata, P.; Ward, K. W.; Hindler, J. A.; Miller, S. A.; Gregson, A. First report of ceftazidime-avibactam resistance in a KPC-3 expressing Klebsiella pneumoniae Antimicrob. Agents Chemother. 2015, 59, 6605-6607 10.1128/AAC.01165-15
15. Papp-Wallace, K. M.; Winkler, M. L.; Taracila, M. A.; Bonomo, R. A. Variants of β-lactamase KPC-2 that are resistant to inhibition by Avibactam Antimicrob. Agents Chemother. 2015, 59, 3710-3717 10.1128/AAC.04406-14
16. Winkler, M. L.; Papp-Wallace, K. M.; Taracila, M. A.; Bonomo, R. A. Avibactam and inhibitor-resistant SHV β-lactamases Antimicrob. Agents Chemother. 2015, 59, 3700-3709 10.1128/AAC.04405-14
17. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery J. Med. Chem. 2008, 51, 3661-3680 10.1021/jm8000373
18. Roughley, S. D.; Hubbard, R. E. How well can fragments explore accessed chemical space? A case study from heat shock protein 90 J. Med. Chem. 2011, 54, 3989-4005 10.1021/jm200350g
19. Danielson, U. Fragment library screening and lead characterization using SPR biosensors Curr. Top. Med. Chem. 2009, 9, 1725-1735 10.2174/156802609790102392
20. Navratilova, I.; Hopkins, A. L. Emerging role of surface plasmon resonance in fragment-based drug discovery Future Med. Chem. 2011, 3, 1809-1820 10.4155/fmc.11.128
21. Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 2010, 53, 2719-2740 10.1021/jm901137j
22. Giannetti, A. M.; Koch, B. D.; Browner, M. F. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors J. Med. Chem. 2008, 4, 574-580 10.1021/jm700952v
23. Giannetti, A. M. from Experimental Design to Validated Hits: A Comprehensive Walk-Through of Fragment Lead Identification Using Surface Plasmon Resonance, 1st ed.; Elsevier Inc.: Cambridge, MA, 2011; Vol. 493.
24. Lund, B. A.; Leiros, H.-K. S.; Bjerga, G. E. A high-throughput, restriction-free cloning and screening strategy based on ccdB-gene replacement Microb. Cell Fact. 2014, 13, 38 10.1186/1475-2859-13-38
25. Petersen, T. N.; Brunak, S.; von Heijne, G.; Nielsen, H. SignalP 4.0: discriminating signal peptides from transmembrane regions Nat. Methods 2011, 8, 785-786 10.1038/nmeth.1701
26. Antunes, N. T.; Lamoureaux, T. L.; Toth, M.; Stewart, N. K.; Frase, H.; Vakulenko, S. B. Class D β-lactamases: are they all carbapenemases? Antimicrob. Agents Chemother. 2014, 58, 2119-2125 10.1128/AAC.02522-13
27. Docquier, J.-D.; Calderone, V.; De Luca, F.; Benvenuti, M.; Giuliani, F.; Bellucci, L.; Tafi, A.; Nordmann, P.; Botta, M.; Rossolini, G. M.; Mangani, S. Crystal structure of the OXA-48 β-lactamase reveals mechanistic diversity among class D carbapenemases Chem. Biol. 2009, 16, 540-547 10.1016/j.chembiol.2009.04.010
28. O'Callaghan, C. H.; Morris, A.; Kirby, S. M.; Shingler, A. H. Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate Antimicrob. Agents Chemother. 1972, 1, 283-288 10.1128/AAC.1.4.283
29. Bebrone, C.; Moali, C.; Mahy, F.; Rival, S.; Docquier, J. D.; Rossolini, G. M.; Fastrez, J.; Pratt, R. F.; Frère, J. M.; Galleni, M. CENTA as a chromogenic substrate for studying β-lactamases Antimicrob. Agents Chemother. 2001, 45, 1868-1871 10.1128/AAC.45.6.1868-1871.2001
30. Biacore Assay Handbook; GE Healthcare Bio-Sciences AB: Uppsala, Sweden, 2012; p 40.
31. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A "Rule of Three" for fragment-based lead discovery? Drug Discovery Today 2003, 8, 876-877 10.1016/S1359-6446(03)02831-9
32. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431 10.1016/S1359-6446(04)03069-7
33. Hopkins, A. L.; Keserü, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. The role of ligand efficiency metrics in drug discovery Nat. Rev. Drug Discovery 2014, 13, 105-121 10.1038/nrd4163
34. Krissinel, E.; Henrick, K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2256-2268 10.1107/S0907444904026460
35. Beck, J.; Vercheval, L.; Bebrone, C.; Herteg-Fernea, A.; Lassaux, P.; Marchand-Brynaert, J. Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D β-lactamase) by screening amino analogs and homologs of citrate and isocitrate Bioorg. Med. Chem. Lett. 2009, 19, 3593-3597 10.1016/j.bmcl.2009.04.149
36. Docquier, J.-D.; Benvenuti, M.; Calderone, V.; Giuliani, F.; Kapetis, D.; De Luca, F.; Rossolini, G. M.; Mangani, S. Crystal structure of the narrow-spectrum OXA-46 class D β-lactamase: relationship between active-site lysine carbamylation and inhibition by polycarboxylates Antimicrob. Agents Chemother. 2010, 54, 2167-2174 10.1128/AAC.01517-09
37. King, D. T.; King, A. M.; Lal, S. M.; Wright, G. D.; Strynadka, N. C. J. Molecular mechanism of Avibactam-mediated β-lactamase inhibition ACS Infect. Dis. 2015, 1, 175-184 10.1021/acsinfecdis.5b00007
38. Szarecka, A.; Lesnock, K. R.; Ramirez-Mondragon, C. A.; Nicholas, H. B.; Wymore, T. The class D β-lactamase family: residues governing the maintenance and diversity of function Protein Eng., Des. Sel. 2011, 24, 801-809 10.1093/protein/gzr041
39. Christopeit, T.; Carlsen, T. J. O.; Helland, R.; Leiros, H.-K. S. Discovery of novel inhibitor scaffolds against the metallo-β-lactamase VIM-2 by surface plasmon resonance (SPR) based fragment screening J. Med. Chem. 2015, 58, 8671-8682 10.1021/acs.jmedchem.5b01289
40. Ulrich, A.; Andersen, K. R.; Schwartz, T. U. Exponential megapriming PCR (EMP) cloning-seamless DNA insertion into any target plasmid without sequence constraints PLoS One 2012, 7, e53360 10.1371/journal.pone.0053360
41. Unger, T.; Jacobovitch, Y.; Dantes, A.; Bernheim, R.; Peleg, Y. Applications of the Restriction Free (RF) cloning procedure for molecular manipulations and protein expression J. Struct. Biol. 2010, 172, 34-44 10.1016/j.jsb.2010.06.016
42. Studier, F. W. Protein production by auto-induction in high-density shaking cultures Protein Expression Purif. 2005, 41, 207-234 10.1016/j.pep.2005.01.016
43. Kabsch, W. XDS Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 125-132 10.1107/S0907444909047337
44. Evans, P. R.; Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr., Sect. D: Biol. Crystallogr. 2013, 69, 1204-1214 10.1107/S0907444913000061
45. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674 10.1107/S0021889807021206
46. Afonine, P. V.; Grosse-Kunstleve, R. W.; Echols, N.; Headd, J. J.; Moriarty, N. W.; Mustyakimov, M.; Terwilliger, T. C.; Urzhumtsev, A.; Zwart, P. H.; Adams, P. D. Towards automated crystallographic structure refinement with phenix.refine Acta Crystallogr., Sect. D: Biol. Crystallogr. 2012, 68, 352-367 10.1107/S0907444912001308
47. Smart, O. S.; Womack, T. O.; Sharff, A.; Flensburg, C.; Keller, P.; Paciorek, W.; Vonrhein, C.; Bricogne, G. Grade, version 1.102; Global Phasing: Cambridge, UK, 2014.
48. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 486-501 10.1107/S0907444910007493
49. Liebschner, D. Phenix.polder-A Tool for Calculating Difference Maps around Atom Selections by Excluding the Bulk Solvent Mask. The Phenix Project: Berkeley, CA, 2016.
50. The PyMOL Molecular Graphics System; Schrödinger LLC: New York, 2014.
51. Laskowski, R. A.; Swindells, M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery J. Chem. Inf. Model. 2011, 51, 2778-2786 10.1021/ci200227u
52. Sherman, W.; Day, T.; Jacobson, M. P.; Friesner, R. A.; Farid, R. Novel procedure for modeling ligand/receptor induced fit effects J. Med. Chem. 2006, 49, 534-553 10.1021/jm050540c
53. Tominaga, M.; Suzuki, K.; Kawano, M.; Kusukawa, T.; Ozeki, T.; Sakamoto, S.; Yamaguchi, K.; Fujita, M. Finite, spherical coordination networks that self-organize from 36 small components Angew. Chem., Int. Ed. 2004, 43, 5621-5625 10.1002/anie.200461422